Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and FutureMatthew Siskin, David R. Wise, Minas P. Economides|Cancers|2025Cited by 12
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate CancerNeil J. Shah, William Oh, Vaibhav G. Patel et al.|JNCI Cancer Spectrum|2022Cited by 11
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)David R. Wise, Kwok‐Kin Wong, Shanmugapriya Selvaraj et al.|Prostate Cancer and Prostatic Diseases|2024Cited by 9
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Minas P. Economides, Scot A. Niglio, Matthew I. Milowsky et al.|Journal of Clinical Oncology|2023Cited by 8
The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.Vaibhav G. Patel, William Oh, Xiaobo Zhong et al.|Journal of Clinical Oncology|2021Cited by 5